Atsena Therapeutics
PrivateLast Round
Series C
Apr 2, 2025
Est. Valuation
$340M
Total Funding Raised
$237.65M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Atsena Therapeutics is a biotechnology company that develops ocular gene therapies aimed at reversing or preventing blindness caused by inherited retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Atsena Therapeutics Comparables
Compare Atsena Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Opus Genetics | 86% | |
| Beacon Therapeutics | 85% | |
| SpliceBio | 81% |
Atsena Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 2, 2025 | ||||
| Series B | Oct 2, 2023 | ||||
| Series A | Dec 16, 2020 | ||||
| Series 1 | Apr 1, 2020 |
Key People
Founding team and executive leadership
Atsena Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series C |
| Lightstone Ventures | Series A, Series C, Series B |
| Hatteras Venture Partners | Series A, Series C, Series B, Series 1 |
| Osage University Partners | Series A, Series C, Series B, Series 1 |
| The Manning Family Foundation | Series A, Series B, Series C |
| PBM Capital Group | Series 1 |
| Abingworth | Series A, Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2026
Grew 15% QoQ, from 39 to 45 employees.
- May 17, 2026
Monthly visitors grew 115% MoM, reaching 18.9K.
Recent news
Latest coverage and updates
- is_developingAug 19, 2026
Atsena Therapeutics, Inc. will develop ATSN-101 for GUCY2D-associated Leber congenital amaurosis type 1, or LCA1 on Oct 1st '26.
- hiresAug 19, 2026
Atsena Therapeutics, Inc. hired Matt Pauls as Board of Directors on Aug 19th '26.
- partners_withJul 23, 2026
Atsena Therapeutics, Inc. will partner with Nippon Shinyaku, Ltd. on Oct 1st '26.
- is_developingJul 23, 2026
Atsena Therapeutics, Inc. will develop ATSN-101 on Oct 1st '26.
Atsena Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Atsena Therapeutics's valuation, stock price, and market status.
Is Atsena Therapeutics a public or private company?
Atsena Therapeutics is a private company.
What is the current stock price of Atsena Therapeutics?
Atsena Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Atsena Therapeutics worth (valuation)?
Valuation information for Atsena Therapeutics is not publicly available.
Can I buy Atsena Therapeutics stock?
Atsena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Atsena Therapeutics's last funding round?
Atsena Therapeutics's most recent funding round was Series C on April 2, 2025.
Who are the main investors in Atsena Therapeutics?
Key investors in Atsena Therapeutics include Bain Capital Life Sciences, Hatteras Venture Partners, Bain Capital, LP, Foundation Fighting Blindness, Sofinnova Investments.
Will Atsena Therapeutics IPO soon?
No public IPO plans have been announced for Atsena Therapeutics.
How can I track Atsena Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Atsena Therapeutics's secondary market activity and sign up for updates.